Many studies have made observations that provide support for the hypothesis of a potential diabetogenic effect of Covid-19; in addition it is well-recognized that stress response associated with severe illness have diabetogenic effect. However, whether the alterations of glucose metabolism that occur with a sudden onset in severe COVIOD-19 persist or remit when the infection resolves is unclear. How frequent is the phenomenon of newonset diabetes, and is it classic type 1 or type 2 diabetes or a new type of diabetes.
Key words: COVID 19; Prediabetes; Diabetes; Pneumonia.
Out of 309 patients 240(77.6) patients had no underlying co morbidity .Hypertension and diabetes was already present in 26(8.41%) patients COPD was present in 4 (1.29%) patients .COPD and hypertension was pre-existing in 7(2.2%) patients and COPD with Diabetes was pre-existing in 5(1.6%) patients .Isolated diabetes was pre-existing in 11(3.5%) patients and isolated hypertension was seen in 6(1.94%) patients and other illness included chronic kidney disease, coronary artery disease, chronic liver disease ,Malignancy was pre-existing in 27(2.9%) patients (Table 3)
The minimum Random blood sugar was 134 and maximum 712mg/dl and the mean blood sugar Random was 270mg/dl (Table 4)
Out of 309 patients 42 (13.59%) had already pre-existing diabetes and 29(9.38%) had diabetes which was first time detected,208 patients (67.3%) had normal blood sugar and 30 patients(9.7%) has impaired blood sugar falling in pre diabetic range at presentation to Emergency room (Table 5 and 6)
Table 1:showing maximum, minimum and mean age of patients |
|||||
No. of Patients |
Minimum age |
Maximum age |
Mean |
Std. Deviation |
|
AGE |
309 |
17 |
90 |
52.21 |
17.698 |
Table 2: showing the gender variable of participating patients. |
||||
Gender |
Frequency |
Percent |
Valid Percent |
Cumulative Percent |
Male |
207 |
67 |
67 |
67 |
Female |
102 |
33 |
33 |
100 |
Total |
309 |
100 |
100 |
Table 3:showing various co morbidities in admitted patients |
|||
Co morbidities |
Frequency |
Percent |
Valid Percent |
None |
240 |
77.6 |
78 |
Diabetes/Hypertension |
26 |
8.41 |
8.4 |
COPD |
4 |
1.29 |
1.3 |
COPD/ Hypertension |
7 |
2.26 |
2.2 |
COPD/ Diabetes |
5 |
1.61 |
1.6 |
Other disease |
9 |
2.91 |
2.9 |
Diabetes |
11 |
3.55 |
3.6 |
Hypertension |
6 |
1.94 |
1.9 |
Total |
103 |
100 |
100 |
Table 4:showing minimum, maximum and mean blood sugar random. |
|||
Number |
Minimum |
Maximum |
|
Blood sugar random |
309 |
76 |
712 |
Valid Number |
309 |
Table 5: showing patients with known diabetes and no history of diabetes at admission. |
||
Frequency |
Percent |
|
No.history of diabetes |
267 |
86.4 |
Known diabetic |
42 |
13.59 |
Total |
309 |
100 |
Table 6:Showing random blood glucose level at admission at categorising 20th patients into normal pre diabetes and diabetes. |
||
Frequency |
Percent |
|
BG<140 |
208 |
67.3 |
BG>140<200 |
30 |
9.7 |
1st time detected BG>200 |
29 |
9.3 |
Known diabetic BG>200 |
42 |
13.6 |
Total |
309 |
100 |
Infection with SARS COV 2 can lead to increased levels of inflammatory mediators in the blood, including lipopolysaccharide[10,11]. Poor glycaemic control predicts an increased need for medications and hospitalizations, and increased mortality[12,13]. Several mechanisms have been proposed by which virally induced inflammation and increases insulin resistance[14].
Multiple studies have been conducted to find the prevalence of diabetes in COVID 19. In six studies, the prevalence of diabetes was ≤10% that it was 128 diabetes patients in 2333 patients with COVID-19 included Wang (15/242)[15] Guan (81/1099)[16] , Wan (12/135)[17] , Hui (2/41)[18], Yang (9/710)[19], and Chen (9/106)[20]. Fourteen studies report prevalence in 10.1–20% that it was 216 diabetes patients in 1559 patients with COVID-19 included Shi (10/81) [21], Zhao (4/37)[22] , Hu (47/323)[23] , Zhang (17/140)[24] , Zhou (36/191)[25] , Wang (54/339)[26], Wang (14/138)[27] , Wu (22/201)[28] , and Liu (12/109)[29] . And three studies report prevalence above 20% that it was 171 diabetes patients in 404 patients with COVID-19 included Xu (147/355)[30] , Bhatraju (14/24) [31], and Li (10/25 death) [32]The results of meta-analysis on 18 studies has 14.5% of the subjects with diabetes, in which there was no publication bias (t = 1.06 P = 0.304).
In our study incidence of diabetes was very high(22.9%) 42 of 309 patients (13.6%) patients had already diabetes and were on treatment at the time of admission to hospital, 29 of 309 (9.3%) patients had new onset diabetes which was diagnosed at time of admission and 30 out of 309 patients (9.7%) had impaired blood sugar at presentation.
1. Only patients with severe COVID 19 Pneumonia were enrolled.
2. There could be high incidence of undiagnosed diabetes in our population.
3. Our population may have some genetic predisposition to diabetes which is activated by COVID 19
- Papadokostaki E, Tentolouris N, Liberopoulos E.COVID-19 and diabetes: what does the clinician need to know? Prim Care Diabetes. 2020;14(5):558-563.doi: 10.1016/j.pcd.2020.06.010.
- Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al.Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19.Diabetes Obes. Metab. 2020;22(10):1897-1906.doi:10.1111/dom.14099.
- Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis. J Pathol.2004;203(2):631-637.doi:10.1002/path.1570.
- Yang J-K, Lin S-S, Ji X-J, Guo L-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol.2010; 47(3):193-199.doi: 10.1007/s00592-009-0109-4.
- YJ Chee, SJH Ng, E Yeoh. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res ClinPract. 2020;164:108166.doi:10.1016/j.diabres.2020.108166.
- C Sardu, N D’Onofrio, ML Balestrieri, M Barbieri, MR Rizzo, V Messina, et al.Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control?Diabetes Care. 2020;43(7):1408-1415.doi: 10.2337/dc20-0723.
- J Li, X Wang, J Chen, X Zuo, H Zhang, A Deng. COVID-19 infection may cause ketosisandketoacidosis.Diabetes ObesMetab. 2020;22(10):1935-1941.doi: 10.1111/dom.14057.
- M Apicella, MC Campopiano, M Mantuano, L Mazoni, ACoppelli, SD Prato.COVID-19 in people with diabetes: understanding the reasons for worse outcomes. The lancetDiabetes& Endocrinology. 2020;8(9).782-792.doi:10.1016/s2213-8587(20)30238-2.
- PK Reddy, MS Kuchay, Y Mehta, SK Mishra. Diabetic ketoacidosis precipitated by COVID-19: a report of two cases and review of literature. Diabetes Metab Syndr.2020;14(5).1459-1462.doi:10.1016/j.dsx.2020.07.050.
- Nansen A, Christensen J P, Marker O, Thomsen A R. Sensitization to lipopolysaccharide in mice with asymptomatic viral infection: role of T cell-dependent production of interferon-gamma. J Infect Dis.1997;176(1):151-157.doi: 10.1086/514017.
- Neu U and Mainou B A. Virus interactions with bacteria: partners in the infectious dance. PLoS Pathog.2020;16(2):e1008234.doi: 10.1371/journal.ppat.1008234.
- Zhu L, ZG She, X Cheng , JJ Qin, XJ Zhang, J Cai, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068-1077.e3.doi: 10.1016/j.cmet.2020.04.021.
- J A Critchley, I M Carey, T Harris, S DeWilde, FJ Hosking, DG Cook. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care. 2018;41(10):2127-2135.doi: 10.2337/dc18-0287.
- M Šestan, S Marinović, I Kavazović, Đ Cekinović , S Wueest, T TWensveen, et al. Virus-induced interferon-γ causes insulin resistance in skeletal muscle and derails glycemic control in obesity. Immunity.2018.17;49(1):164-177.e6.doi: 10.1016/j.immuni.2018.05.005.
- J Zhou, J Sun, Z Cao, W Wang, K Huang, F Zheng, et al. Epidemiological and clinical features of 201 COVID-19 patients in Changsha city, Hunan, China.Medicine (Baltimore). 2020; 99(34): e21824.doi:10.1097/MD.0000000000021824.
- Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med.2020; 382:1708-1720.doi:10.1056/NEJMoa2002032.
- Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing. J Med Virol. 2020;92(7):797-806.doi: 10.1002/jmv.25783.
- Hui H, Zhang Y, Yang X, Wang X, He B, Li L, et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. medRxiv; 2020.doi:10.1101/2020.02.24.20027052.
- Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.doi:10.1016/S2213-2600(20)30079-5.
- Chen X, Hu W, Ling J, Mo P, Zhang Y, Jiang Q, et al. Hypertension and diabetes delay the viral clearance in COVID-19 patients. medRxiv. 2020.doi:10.1101/2020.03.22.20040774.
- Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425-434.doi:10.1016/S1473-3099(20)30086-4.
- Zhao S, Ling K, Yan H, Zhong L, Peng X, Yao S, et al. Anesthetic management of patients with COVID 19 infections during emergency procedures.J CardiothoracVascAnesth. 2020;34(5):1125-1131.doi:10.1053/j.jvca.2020.02.039.
- Hu L, Chen S, Fu Y, Gao Z, Long H, Ren H-W, et al. Risk factors associated with clinical outcomes in 323 COVID-19 patients in Wuhan, China. medRxiv. 2020. doi:10.1101/2020.03.25.20037721.
- Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75(7):1730-1741.doi: 10.1111/all.14238.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.doi: 10.1016/S0140-6736(20)30566-3.
- Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80(6):639-645.doi: 10.1016/j.jinf.2020.03.019.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.doi: 10.1001/jama.2020.1585.
- Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(7): 1–11.doi:10.1001/jamainternmed.2020.0994.
- Liu Y, Sun W, Chen L, Wang Y, Zhang L, Yu L. Clinical characteristics and progression of 2019 novel coronavirus-infected patients concurrent acute respiratory distress syndrome. medRxiv; 2020.doi:10.1001/jamainternmed.2020.0994.
- Xu S, Fu L, Fei J, Xiang H-X, Xiang Y, Tan Z-X, et al. Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis. medRxiv. 2020.doi:10.1101/2020.03.24.20042408.
- Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382(21):2012-2022.doi: 10.1056/NEJMoa2004500.
- Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94:128-132.doi: 10.1016/j.ijid.2020.03.053.